-
Ponatinib, sold
under the
brand name Iclusig, is a
medication used for the
treatment of
chronic myeloid leukemia and
Philadelphia chromosome–positive...
-
resulted in what is now
known as the
compound ponatinib. X-ray
crystallographic analysis of
ponatinib and T315I Bcr-Abl
mutated kinase display that the...
- emergency-access
program for
Ponatinib,
which provided drugs to
patients in need
during this six-w**** period.
Ponatinib remained on the
market in all...
- T315I, as well as all
other known mutations of the oncoprotein. The drug,
ponatinib,
gained FDA
approval in
December 2012 for
treatment of
patients with resistant...
- Angelica; Zhang, Qinkun; Prabhu,
Sumanth D.; Lal, Hind (2023-02-03). "
Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β
Mediated Inflammation"...
- (Ruxolitinib),
Tabrecta (capmatinib),
Olumiant (Baricitinib), and
Iclusig (
ponatinib). In 2013,
Novartis acquired Incyte's c-Met
inhibitor capmatinib (INC280...
- (Sprycel)
Lapatinib (Tykerb)
Nilotinib (Tasigna)
Bosutinib (Bosulif)
Ponatinib (Iclusig)
Asciminib (Scemblix)
Bortezomib (Velcade) is an apoptosis-inducing...
-
mutation that
affects most ATP-competitive
active site inhibitors,
except ponatinib.
Common side
effects of
Asciminib are
symptoms of a cold,
muscle pain...
-
Mitoxantrone Nelarabine Nilotinib Oblimersen Pegaspargase Pentostatin Ponatinib Prednisone Rituximab Tretinoin Vincristine "Drugs
Approved for Leukemia...
-
inhibitors to
treat CML are imatinib, dasatinib, nilotinib,
bosutinib and
ponatinib.
Gastrointestinal stromal tumors (GIST) are
known to
withstand cancer...
